Patients with suspected NAFLD (e.g., those with prediabetes, type 2 diabetes mellitus, pre-obesity/obesity, increase in ALT or AST) may undergo non-invasive screening using the scores previously mentioned, with some preferring the Fibrosis-4 index/calculator [3,14]. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.